A Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B

Sponsor

3M Pharmaceuticals

Principal Investigator

Dr. Paola Gehrig, Obstetrics and Gynecology

Project Run Dates

3/24/2006 to 6/1/2009

 

Summary

The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.

 

Associated Publications and other materials

Study Record Detail on Clinical Trials.gov